Search
Results: 1
Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
Shreeya Patel, Rosa Legood, D Gareth Evans, Clare Turnbull, Antonis C Antoniou, Usha Menon, Ian Jacobs, Ranjit Manchanda
Mar 09, 2018
BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effective compared with family history based testing in Ashkenazi Jewish women. However, only 1 of the 3 Ashkenazi Jewish...
BRCA Sephardi Jewish cost effectiveness population testing Adult Cost-Benefit Analysis Female Genes BRCA1 Genetic Testing Hereditary Breast and Ovarian Cancer Syndrome Heterozygote Hormone Replacement Therapy Humans Jews Life Expectancy Magnetic Resonance Imaging Mammography Markov Chains Middle Aged Mutation Ovariectomy Prophylactic Mastectomy Prophylactic Surgical Procedures Quality-Adjusted Life Years United Kingdom United States